Teon Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
Phase 1
Terminated
- Conditions
- CancerAdvanced CancerAdvanced Solid TumorOncology
- Interventions
- Drug: A PD-1 inhibitor
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Teon Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05525455
- Locations
- 🇺🇸
Teon Investigational Site, Fairfax, Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath